SINGAPORE, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - How much sugar does a Singaporean typically take in a day? In a recent speech by Health Minister Mr. Ong Ye Kung, Singapore is too sweet. While the average daily sugar intake of Singaporeans has fallen from 60g in 2018 to 56g in 2022, this number still works out to about 11 teaspoons of daily sugar consumption, about 10% higher than the ideal intake of less than 50g.Amid an ageing population, the younger generation in Singapore is also increasingly affected by this chronic condition, highlighting a growing national health concern related to sugar consumption.Sugar, a common mis-solution to anxiety, often provides a sense of fleeting comfort. The instant boost in dopamine from sugar can create a cycle of dependency, giving temporary relief from stress or anxiety but contributing to harmful physical effects, such as inflammation, weight gain, and insulin resistance.The overconsumption of sugar, combined with sedentary lifestyles and other unhealthy dietary habits have contributed to diabetes becoming a major global health crisis today – Alarmingly, diabetes rates are rising among the younger generation, including both teenagers and young adults, contributing to nearly half a million cases in Singapore. Astonishingly, 40% of Singaporeans remain unaware of their pre-diabetic status, an often silent condition that could lead to type 2 diabetes.Diabetes is a chronic condition that if left unmanaged, can lead to serious health complications, including an increased risk of cardiovascular disease, kidney failure, nerve damage or even vision loss. However, type 2 diabetes can be prevented through proactive lifestyle changes, including healthy eating, regular physical activity, so as to maintain optimal blood sugar levels.In line with World Diabetes Day on 14 November, LAC (pronounced as L-A-C) is dedicated to highlight the importance of taking preventative measures against diabetes. By incorporating supplements that support blood sugar regulation and reduce carbohydrate absorption, along with a healthy diet and increased physical activity, individuals can maintain their glucose levels and maintain their metabolic health.LAC GlucoX is designed to support healthy glucose levels. Formulated with bitter melon and Fibersol-2, Banaba leaf, Gymnema, Chromium and Brown Seaweed, GlucoX helps slow down carbohydrate absorption and optimises glucose utilisation, supporting individuals in managing their blood sugar levels effectively.LAC Bitter Melon Formula, is formulated with Momordica Charantia Polysaccharide (MCP), a key compound from bitter melon known for its ability to support healthy blood glucose levels. It enhances the body’s ability to regulate insulin production and supports the overall metabolic health of individuals. Copyright 2024 ACN Newswire via SeaPRwire.com.
SAN FRANCISCO, CA & MUMBAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - CleverTap, the all-in-one engagement platform, has released its market research report on “The State of App and Web User Experience Optimization”. The report sheds light on how digital-first brands are leveraging experimentation and personalization on their apps and websites to drive customer engagement and business growth. It also highlights roadblocks faced by marketers and product managers while experimenting with the UI, workflows, and functionality across apps and websites.For a thorough understanding of the current landscape, this report draws insights from a diverse group of respondents – with data gathered through structured surveys and in-depth interviews – representing organizations with over two million customers across 50+ countries. This includes VPs, CMOs, and product managers ranging from startups to large enterprises across various industries. – Together, they offer valuable insights into how businesses optimize app and web experiences to drive customer engagement and business growth.While 95% of surveyed product managers and 88% of marketers believe that the right user experience is essential for driving customer engagement and retention — many report significant challenges to effectively experimenting with app and web user experiences. Despite recognizing its importance, they reported difficulties such as limited resources, data gaps, and technical constraints that hinder their ability to innovate and deliver impactful user experiences. Other notable findings from the report include -81.9% of product managers rarely experiment with their app and web experiences before making changes to them. The top challenges quoted include lack of resources (46%), inadequate data and analytics (31%), and technical issues (19%)54% of product managers are unable to support marketers in experimenting with onboarding flows, banner placement, homepage content and other similar app and web experiences.81% of marketers believe it would make a significant impact if they could independently experiment with multiple variations of web and app experiences within a no-code framework provided by their product management function.Commenting on the report, Jacob Joseph, Vice President - Data Science, CleverTap said, “With consumer expectations constantly rising, brands need to go beyond perfecting their channel strategies and also focus on enhancing the in-app and web experiences to drive results from their marketing efforts. Since all channels ultimately lead users to the app or website, an unsatisfactory experience there can render all your efforts ineffective and become a missed opportunity. Personalization and experimentation on apps and websites are critical to reducing churn and driving growth, yet resource constraints and data gaps hinder marketers and product managers. We are committed to helping businesses navigate these challenges with CleverTap’s Product Experiences, which offers effortless ways to personalize and experiment with app and web experiences driving stronger engagement and lasting brand loyalty."For more information and insights download the report here. About CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Decathlon, Domino’s, Levis, Jio, Emirates NBD, Puma, Croma (A Tata Enterprise), Swiggy, SonyLIV, Axis Bank, AirAsia, TD Bank, Ooredoo, and Tesco to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit clevertap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/ X: https://twitter.com/CleverTap Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications, CleverTap+91 9820900036sony@clevertap.comASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.
- Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission.- In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved immunological complete remission by week 24.- EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported.SHANGHAI, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK,“Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. In an analysis of the data available as of September 13th, 2024, results from the Phase 1b/2a clinical trial showed that for patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission1 and 10 out of 11 (91%) achieved immunological complete remission (ICR)2. In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved ICR by week 24.EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of autoimmune renal diseases. Compared to covalent irreversible BTK inhibitors, EVER001 offers improved selectivity while maintaining high potency, thereby potentially avoiding many of the side effects associated with earlier-generation BTK inhibitors. Everest Medicines holds global rights to EVER001 for the treatment of renal diseases.The Phase 1b/2a clinical trial of EVER001 for the treatment of pMN is an ongoing trial conducted in China. A total of 31 patients with biopsy-proven pMN who tested positive for anti-PLA2R autoantibodies were enrolled into two cohorts. The total treatment duration was 36 weeks. Based on the patient data collected by September 13th, 2024, in the low-dose cohort, the geometric least squares mean 24-hour proteinuria decreased by 78.3% at week 36 compared to baseline, while the high-dose cohort achieved a 73.8% reduction by week 24. EVER001 treatment induced greater than 90% reductions in anti-PLA2R antibody as early as week 24 in the low-dose cohort and week 12 in the high-dose cohort. EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported."We are excited to see the encouraging results in this preliminary analysis of our Phase 1b/2a clinical proof-of-concept trial of EVER001. This demonstrates the potential of EVER001 as a next-generation BTK inhibitor for the treatment of various autoimmune renal diseases, including pMN. "Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said："This data release marks the first time Everest Medicines has disclosed results from its global pipeline. We look forward to completing this trial and sharing detailed data in future conferences and publications. Moving forward, we will continue to drive the global clinical development of EVER001, to meet patients' urgent clinical needs.”Membranous nephropathy is a common pathological type of nephrotic syndrome in adults, and its prevalence in China has been increasing, ranking second only to IgA nephropathy3. There are about 2 million patients with pMN in China, with an estimated 80,000 to 100,000 patients in the United States, 80,000 in Europe, and 40,000 in Japan. There are no approved drugs for this indication worldwide. The current treatment goal is to improve remission rates, reduce high relapse rates, and minimize the risk of chronic toxicity caused by currently available treatments. More than one-third of pMN patients still progress to end-stage renal disease under current standards of care.This Phase 1b/2a clinical trial was approved by the Center for Drug Evaluation of the National Medical Products Administration in September 2022 to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of EVER001 in Chinese patients with glomerular diseases characterized by proteinuria. The previously published results of a Phase 1 study conducted in healthy Chinese and Australian subjects conducted by SinoMab BioScience indicate that EVER001 has high selectivity, excellent pharmacokinetic properties, a good safety profile, and strong target binding.About EVER001EVER001 (previously known as XNW1011) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases. Based in part on results from a completed phase 1 trial with healthy subjects conducted by SinoMab in China, EVER001 exhibited high selectivity, excellent pharmacokinetics properties, strong target binding and a safety profile that supports continued clinical development.Under an exclusive licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience, Everest owns global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases.Investor Calls InformationEverest Medicines will hold investor calls on the data results from EVER001 Phase 1b/2a clinical study in primary membranous nephropathy. EVER001 is a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, and Everest owns the global rights to develop EVER001 for the treatment of renal diseases.The English session of the conference call will be held at 9:00 AM on Dec. 4, 2024, Beijing Time (8:00 PM U.S. Eastern Time on Dec. 3, 2024) and the Mandarin session of the conference call will be held at 10:30 AM Beijing Time on the same day (9:30 PM U.S. Eastern Time on Dec. 3, 2024).The conference calls can be accessed by the following links:For English Session:Time: 9:00 AM Beijing Time, Wednesday, Dec. 4, 2024 (8:00 PM U.S. Eastern Time on Dec. 3, 2024)Pre-Registration Link: https://www.acecamptech.com/eventDetail/60510700Webcast Link:https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700Alternatively, participants may dial in to the conference call using below dial-in information:United States: +1-646-2543594 (EN)Chinese Mainland: +86-10-58084166 (EN), +86-10-58084199 (CN)Hong Kong, China: +852-30051313 (EN), +852-30051355 (CN)United Kingdom: +44-12-1368-0466 (EN)International: +1-866-6363243 (EN)Password: 842080For Mandarin Session:Time: 10:30 AM Beijing Time, Wednesday, Dec. 4, 2024 (9:30 PM U.S. Eastern Time on Dec. 3, 2024)Webcast Link: https://s.comein.cn/n3arj55sAlternatively, participants may dial into the conference call using below dial-in information:United States: +1-646-3578788, +1-408-7093255Chinese Mainland: 400-969-8928, 400-806-3263Hong Kong, China: +852-301-83602Taiwan, China: +886-226563394, +886-277417882Singapore: +65-64075649, +65-66220840United Kingdom: +44-2070970018 International: +86-2362737123Password: 377570The replay of English session will be available shortly after the call and can be accessed by visiting the Company’s website at http://www.everestmedicines.com.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.References:1.Overall clinical remission (complete remission or partial remission): 24h proteinuria complete remission (CR): 24h proteinuria < 0.3g/24 h; 24h proteinuria partial remission (PR): 24h proteinuria < 3.5g/24h, but ≥0.3g/24 h, and reduction > 50%, regardless of eGFR or the serum albumin level from baseline.2. Immunological complete remission (ICR): anti-PLA2R titer < 20RU/ml (negative).3. Expert consensus on the application of rituximab in the treatment of membranous nephropathy, Chin J Intern Med, March 2022, Vol. 61, No. 3. Copyright 2024 ACN Newswire via SeaPRwire.com.
TSUKUBA, Japan, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Polymers, such as plastics, are essential in many aspects of life and industry, from packaging and cars to medical devices and optic fibres. Their value comes from diverse properties that are largely determined by their monomers – the single chemical units – that make up a polymer. Unfortunately, it can be challenging to control the chemical behaviour of monomers during manufacture to achieve a desired outcome.The flow synthesis reactor with two bottles containing a monomer, initiator and solvent mixed using a micromixer. The synthesis is controlled with AI-based design of experimental conditions such as the temperature and a flow rate. Now, a team of researchers led by Professor Mikiya Fujii of the Nara Institute of Science and Technology in Japan have used machine learning to mathematically model the polymerization process and reduce the need for time-consuming and expensive experimentation. Their results have been published in the journal Science and Technology of Advanced Materials: Methods.Machine learning algorithms need data, so the researchers designed a polymerization process that would quickly and efficiently generate experimental data to feed into the mathematical model. The target molecule was a styrene-methyl methacrylate co-polymer, which was made by mixing styrene and methyl methacrylate monomers, both already dissolved in a solvent with an added initiator substance, then heating them in a water bath.The team also used a method called flow synthesis, in which the two monomer solutions are mixed and heated in a constant flow. This allows for better mixing, more efficient heating, and more precise control of heating time and flow rate, which makes it ideal for use with machine learning.The modelling evaluated the effect of five key variables in the polymerization process: the concentration of the initiator, the ratio of solvent to monomer, the proportion of styrene, the temperature of the reaction, and the time spent in the water bath. The goal was to have an end product with as close to 50% styrene as possible.Once enough experimental data was available, the machine learning process took only five cycles of calculation to achieve the ideal proportion of styrene to methyl methacrylate. The results showed that the key was a lower temperature and longer time in the water bath, as well as lowering the relative concentration of the monomer in the solvent. The researchers were surprised to discover that the solvent concentration was just as important as the proportion of monomers going into the mix.“Our results demonstrate that machine learning not only can explicitly reveal what humans may have implicitly taken for granted but can also provide new insights that weren’t recognized before,” Professor Mikiya Fujii says. “The use of machine learning in chemistry could open the door for smarter, greener manufacturing processes with reduced waste and energy consumption.”Further informationMikiya FujiiNara Institute of Science and TechnologyEmail: fujii.mikiya@ms.naist.jp Paper: https://doi.org/10.1080/27660400.2024.2425178About Science and Technology of Advanced Materials: Methods (STAM-M)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-M Dr Yasufumi NakamichiSTAM Publishing DirectorEmail: NAKAMICHI.Yasufumi@nims.go.jp Press release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2024 ACN Newswire via SeaPRwire.com.
TOKYO, Dec 3, 2024 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. and its rugby team, MIE Honda HEAT, today held a rally event at the Aoyama Welcome Plaza in the Honda Global Head Office in Tokyo, ahead of the NTT Japan Rugby League One 2024-2025 season, which begins on Saturday, December 21, 2024.At the event, Manabu Ozawa, a Managing Executive Officer of Honda concurrently serving as Executive Advisor of MIE Honda HEAT, introduced the Honda vision for its sports activities – to increase the number of people who take on challenges through sports activities and make the lives of all people more enjoyable. He also announced the MIE Honda HEAT team value – “BIND” All Dreams – which was newly established in the pursuit of the team’s vision to become “the strongest, most respected, most loved” team. The “team value” represents the team’s desire to “take on challenges and chase dreams together with all people involved with MIE Honda HEAT.”Other key staff members and players on the team who expressed their strong passion and commitment for the upcoming season included Head Coach Kieran Crowley, General Manager Yoshihito Maeda, the new captain Takumi Fujii, and other key players, including Lemeki Lomano Lava, who returned to the team for the first time in four years. The MIE Honda HEAT was founded in 1961, as the Honda rugby team based in the City of Suzuka, in Mie Prefecture, Japan. Since last season (2023-2024 season), the team has been taking on challenges competing in Division 1, the top division of the Japan Rugby League One. Working toward its goal to become the No. 1 team in Japan in three years’ time, the MIE Honda HEAT has been pursuing continuous initiatives to enhance its strength. In the meantime, in September of this year, the team announced its plan to relocate the base of activities to Utsunomiya City, Tochigi Prefecture sometime prior to the start of the 2026-2027 season, in order to offer more people the opportunity to see the team and get involved in its challenges toward its goal.Based on the company’s vision for its sports activities, Honda will continue to support various athletes who take on challenges toward the realization of their own dreams.Comment of Manabu Ozawa, Managing Executive Officer of Honda Motor Co., Ltd.“Honda sports teams, including the Honda Running Team, have inspired many people this year with their remarkable achievements, expanding their activities from Japan to the world. Our rugby team, getting ready for its second season with the new head coach Kieran Crowley, has built a team structure that reflects the strong will of Coach Crowley to achieve our goal to become the No. 1 team in Japan in three years’ time. We are committed to strengthening MIE Honda HEAT as a sports team that represents Honda corporate culture, demonstrating the collective strengths and teamwork of Honda. In two years, the team is relocating the base of its activities to Tochigi Prefecture, and will continue to strive for further growth. MIE Honda HEAT will continue to take on bold challenges and prove the power of believing in “The Power of Dreams” by playing matches that move people’s hearts. Thank you in advance for your continued support and cheers in the 2024-25 season.”Comment of Kieran Crowley, Head Coach of MIE Honda HEAT“The 2023-24 season, my first year as head coach, was a very difficult one, with only one win out of 16 games. Based on what I perceived as our challenges throughout the season, I brought in 14 new players during the off-season and also added new coaches. As a result of intense competition for positions within the team and the rigorous training experienced by all players, we have built a team with strong physical capability and the stamina to play 80 minutes at full strength. With a goal to be ranked sixth or above in the league, we will further improve our performance in the 2024-25 season, which will start soon. Please keep your expectations high for the great effort and performance of MIE Honda HEAT!”MIE Honda HEAT official website: https://www.honda-heat.jp/ (Japanese/English)Honda Sports Activity website:https://global.honda/jp/brand/sports/ (Japanese)JAPAN RUGBY LEAGUE ONE:https://league-one.jp/ (Japanese)https://league-one.jp/en/ (English) Copyright 2024 JCN Newswire via SeaPRwire.com.
SINGAPORE, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - OKX, the leading cryptocurrency exchange, has partnered with DeAgentAI, the first AI-driven feedback incentive protocol in Web3, to launch an exclusive airdrop campaign. Starting December 3rd, users can complete simple tasks on OKX Wallet to win a share of $50,000 worth of DA tokens.Click here to join the campaign: https://www.okx.com/web3/giveawayParticipating in the DeAgentAI and OKX Wallet airdrop is easy. Download the OKX Wallet, follow DeAgentAI social media networks, and complete a few simple tasks such as sharing campaign posts, and you can claim your rewards. The campaign runs from December 3rd for two weeks-don't miss out!This collaboration brings users unparalleled opportunities to explore advanced AI technology while enjoying the benefits of a secure and user-friendly wallet. With rewards of $50,000 worth of DA tokens, the initiative encourages users to explore Web3 in an innovative and incentivized environment. DeAgentAI and OKX Wallet aim to foster adoption and empower users in the rapidly evolving crypto space.About DeAgentAIDeAgentAI is a trailblazer in Web3 technology, introducing the first AI feedback mechanism incentive protocol that achieves "proof of insight" by integrating user feedback into the model training process. Its flagship product, AlphaX, combines advanced MOE and Transformer architectures to predict BTC and ETH price trends with over 80% accuracy.What is OKX's Web3 Wallet?OKX Wallet complements this innovation with its secure and user-friendly interface tailored for decentralized finance (DeFi) and Web3 applications. As a leading wallet in the crypto space, OKX Wallet enables seamless integration with platforms like DeAgentAI, empowering users to engage in token giveaways, explore cutting-edge AI tools, and participate in the rapidly growing Web3 ecosystem.Contact InformationYves-Alexandre d'OuradouFounderdeagent.ai@gmail.com(001) 2024989991Source: DeAgentAI Copyright 2024 ACN Newswire via SeaPRwire.com.
SAN DIEGO, CA, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - The Japan Maritime Self-Defense Force (JMSDF) has selected the General Atomics Aeronautical Systems, Inc. (GA-ASI) SeaGuardian® Remotely Piloted Aircraft (RPA) systems for its Long Endurance Unmanned Aerial Vehicle program. This follows JMSDF use of SeaGuardian since May 2023 as part of its Medium-Altitude, Long Endurance (MALE) RPA System Trial Operations Project.SeaGuardian has been used by JMSDF to conduct various tests including whether unmanned aircraft can supplant some of the missions currently accomplished with manned aircraft. SeaGuardian is a MALE RPA system that can fly for 24 hours or more, depending on the configuration.GA-ASI has strengthened its Maritime Wide Area Surveillance (MWAS) for Japan with Optix+, which gathers information from the SeaGuardian sensors, as well as other data sources, displaying the full picture of surveillance information for its operator. This functionality makes it easy to task and direct its Intelligence, Surveillance and Reconnaissance (ISR) information in real time. GA-ASI's Optix+ software suite rapidly correlates and exploits collected data into an easily shared common operational picture. Having multi-source correlated data enables automatic detection of anomalous behaviors over waters.SeaGuardian features two multi-mode maritime surface-search radars with an Inverse Synthetic Aperture Radar (ISAR) imaging mode, an Automatic Identification System (AIS) receiver, and a High-Definition - Full-Motion Video sensor equipped with optical and infrared cameras as well as electronic intelligence receivers. This sensor suite enables real-time detection and identification of surface vessels over thousands of square nautical miles and provides automatic tracking of maritime targets and correlation of AIS transmitters with radar and electronic intelligence tracks.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.For more information, visit www.ga-asi.com .Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.
Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - December 3, 2024) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") a leading North American exploration company focused on critical minerals, acknowledges today's announcement by China banning exports of gallium, germanium, and antimony to the United States. This move underscores the urgent need for Western nations to secure reliable long-term sources of these essential materials.Antimony, a critical component in military applications, energy storage, and advanced manufacturing, is now at the forefront of the global supply chain crisis. China's ban, coupled with existing restrictions that came into effect September 15, 2024, has already sent antimony prices soaring by over 228% this year(1). The Western world faces mounting pressure to address its reliance on China for strategic resources critical to national defense and technological innovation. This ban comes at a time when defense sector inventories are at already concerningly low levels.(2)Military Metals recent antimony mineral project acquisitions in Slovakia, Nova Scotia, and Nevada provide shareholders with a pure antimony play with a diverse portfolio in top jurisdictions."This announcement from China reinforces the importance of Military Metals' mission to secure a sustainable, independent future supply chain for critical minerals," said Scott Eldridge, CEO of Military Metals Corp. "The West can no longer afford to rely on adversarial nations for resources essential to our security and economic stability. We are taking proactive steps to meet this growing demand with future domestic and allied sources of antimony."As geopolitical tensions escalate and the trade war intensifies, Military Metals will continue to prioritize the development of critical mineral resources and work closely with governments and industry partners to ensure the West remains resilient and self-sufficient.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release include exploration activities, and assumptions related to the continuation of the global demand for antimony. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the properties that are the subjects of this news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact both and any future activities in respect of the properties.. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.(1)Reuters; China bans export of critical minerals to US as trade tensions escalate; By Amy Lv and Tony Munroe; December 3, 2024(2)Heritage Foundation: commentary/It’s Past Time to Re-Supply Our Munitions-Depleted U.S. Navy by Jim Fein; June 17, 2024To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232325 Copyright 2024 ACN Newswire via SeaPRwire.com.
